Log in

OTCMKTS:CTDHCTD Stock Price, Forecast & News

-0.01 (-5.26 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $0.18
50-Day Range
MA: $0.18
52-Week Range
Now: $0.18
Volume785,354 shs
Average Volume408,301 shs
Market Capitalization$21.90 million
P/E RatioN/A
Dividend YieldN/A
CTD Holdings, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. CTD Holdings, Inc. was founded in 1990 and is based in Gainesville, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Industrial organic chemicals
Current SymbolOTCMKTS:CTDH



Sales & Book Value

Annual Sales$1.01 million
Book Value($0.01) per share


Net Income$-7,530,000.00
Net Margins-743.08%


Market Cap$21.90 million
Next Earnings Date6/3/2020 (Estimated)
OptionableNot Optionable

Receive CTDH News and Ratings via Email

Sign-up to receive the latest news and ratings for CTDH and its competitors with MarketBeat's FREE daily newsletter.

CTD (OTCMKTS:CTDH) Frequently Asked Questions

How has CTD's stock been impacted by COVID-19 (Coronavirus)?

CTD's stock was trading at $0.1155 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTDH shares have increased by 55.8% and is now trading at $0.18. View which stocks have been most impacted by Coronavirus.

When is CTD's next earnings date?

CTD is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for CTD.

Has CTD been receiving favorable news coverage?

News stories about CTDH stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CTD earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCTD.

Who are some of CTD's key competitors?

What other stocks do shareholders of CTD own?

Who are CTD's key executives?

CTD's management team includes the following people:
  • Mr. N. Scott Fine, Chairman & CEO (Age 62)
  • Dr. Jeffrey L. Tate, COO & Director (Age 61)
  • Dr. Sharon H. Hrynkow, Chief Scientific Officer, SVP of Medical Affairs & Member of Scientific Advisory Board (Age 59)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 74)

What is CTD's stock symbol?

CTD trades on the OTCMKTS under the ticker symbol "CTDH."

How do I buy shares of CTD?

Shares of CTDH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CTD's stock price today?

One share of CTDH stock can currently be purchased for approximately $0.18.

How big of a company is CTD?

CTD has a market capitalization of $21.90 million and generates $1.01 million in revenue each year. CTD employs 5 workers across the globe.

What is CTD's official website?

The official website for CTD is www.ctd-holdings.com.

How can I contact CTD?

CTD's mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32616. The biotechnology company can be reached via phone at 386-418-8060.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.